Tag Archives: immunotherapy

zoom
-

A New Era of Cancer Care

Advances in science and technology have brought about a new wave of promising cancer immunotherapies, which harness the body’s immune system to detect and fight cancer. Researchers have coined immunotherapy as the “beginning to the end of cancer” and we continue to see the space flourish.

Continue reading

zoom
-

Interview with Cheddar: Solving Unmet Need in Melanoma

I had the great privilege of speaking with Cheddar about the importance of cancer immunotherapy and OncoSec’s role in the fight to end cancer. We discuss the advantages of intratumoral therapy, the future of cancer care, and how OncoSec is positioned to solve a great unmet need in oncology. Check out the full interview for more!

zoom
diversity, workforce, immigration, millennials, donald trump, biotech, healthcare, technology, innovation
-

Why Diversity Is Essential

In President Donald Trump’s address to joint sessions of Congress, he announced the White House is planning to unveil a new executive order on immigration tailored to respond to recent court rulings. As you may know, federal judges put a hold on the President’s original executive order banning travelers from seven majority-Muslim countries to enter the US.

Continue reading

zoom
sunset
-

A Patient’s Perspective

Immunotherapy is changing the way we perceive and treat cancer. Advances in science and technology have brought about a new wave of promising cancer immunotherapies, which harness the immune system to fight disease. Melinda Welsh documented her diagnosis and treatment of squamous cell carcinoma of the head and neck with ImmunoPulse IL-12 in the Los Angeles Times.

zoom
-

Doctor, Quit Yellen at Janet

Last month, the Chair of the Federal Reserve, Janet Yellen, made headline news when she weighed in on stock valuations in her semiannual monetary policy report. In her testimony before the Senate Banking Committee, Dr. Yellen made the following statement:

Continue reading

zoom
-

2014 Annual Letter To OncoSec Shareholders

A Letter to Our Shareholders

This is an important moment in cancer immunotherapy and we believe OncoSec is poised to make a real impact. During this pivotal time, it is important that we outline the core fundamentals of our company and our technology, so that you as shareholders will understand why all of us here at OncoSec are excited for the future.

Continue reading

zoom
-

2014 Is Poised to be a Breakout Year for Cancer Immunotherapy

In the December 2013 issue of Science, Cancer Immunotherapy was named as the Breakthrough of the Year.   My initial reaction to this was a little shocking and wondering what finally swayed the sceptics to realize this?  Internally, we have been calling it a breakthrough for sometime, what did we mean by calling it a breakthrough in the first place?

Continue reading

-

Sachs Cancer Bio Partnering Forum

130522 sachs_associates

The Sachs Cancer Bio Partnering Forum, presented by Sachs Associates, brings together business and scientific leaders from cancer research institutes, advocacy groups, pharmaceutical companies and biotech corporations, to assist in investment and funding opportunities. With over 300 representatives in these areas, this year’s presentations covered a wide range of topics, over the span of the two-day event.

Continue reading